HPV E6 Small-Molecule Inhibitors That Restore p53 Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HPV vaccines are ineffective for treating established HPV infections and associated pre-malignant or malignant diseases, and existing treatments for HPV-related cancers are invasive, costly, and carry significant morbidity.
Innovation Solution
Development of small molecule compounds that covalently bind to the HPV E6 protein, disrupting its interaction with E6AP and restoring p53 function, thereby inhibiting viral replication and tumor progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard destructive remedies are used for HPV infections, then treatment effectiveness is achieved, but patient morbidity and potential complications increase
Solution Approach 1:
The patent introduces small molecule compounds as intermediary substances that bind to the HPV E6 protein, disrupting the E6-E6AP-p53 interaction pathway. These compounds act as mediators between the virus and host cell mechanisms, blocking viral oncoprotein function without requiring destructive surgical intervention, thereby maintaining treatment effectiveness while reducing patient morbidity
Solution Approach 2:
The invention replaces mechanical destructive remedies (surgical procedures, radiation, chemotherapy) with a biochemical mechanism-based small molecule therapy. The compounds substitute physical destruction with molecular-level inhibition of viral protein function, achieving cancer treatment through biochemical pathways rather than mechanical or radiological methods, thus reducing complications and morbidity
2Reliability
If HPV E6 protein function is maintained, then viral replication and cell transformation are supported, but tumor suppression is compromised
Solution Approach 1:
The small molecule compounds selectively extract or remove the oncogenic function of the E6 protein by binding to its E6AP interaction surface. This extraction of harmful function allows the virus to maintain replication while preventing the E6-mediated degradation of p53, thereby separating viral propagation from carcinogenic transformation
Solution Approach 2:
The compounds convert the harmful E6-E6AP interaction into a beneficial therapeutic effect by blocking this interaction. The binding of small molecules to the E6 protein's LxxLL motif binding pocket prevents E6AP recruitment, thereby preventing p53 degradation and restoring tumor suppression while allowing controlled viral dynamics
3Reliability
If existing HPV vaccines are administered, then prophylactic protection is achieved, but therapeutic effect for established infections is absent
Solution Approach 1:
Instead of using vaccines to prevent infection (prophylaxis), the invention inverts the approach by using small molecule compounds to treat established infections and cancers. The therapy targets the E6 protein function in already-infected cells, reversing the traditional prevention-only paradigm to include active treatment of persistent infections and HPV-related malignancies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce HPV DNA, treat pre-malignant infected tissues, and inhibit HPV-induced cancers by blocking HPV E6 functions, offering a less invasive and more effective therapeutic approach.
Implementation Method 1
The compounds disclosed herein covalently bind within this pocket, or 'hot spot' in HPV E6, such as HPV16 E6, and irreversibly block its interactions with E6AP
Data Source
AI summary
Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.